The short version of receptor targets fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-12 and is reviewed periodically as new material appears.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
==== MeSH E05.478.567 – immunoassay ==== MeSH E05.478.567.320 – immunoblotting MeSH E05.478.567.320.200 – blotting, western MeSH E05.478.567.320.200.200 – blotting, far-western MeSH E05.478.567.350 – immunoenzyme techniques MeSH E05.478.567.350.170 – enzyme-linked immunosorbent assay MeSH E05.478.567.350.180 – enzyme multiplied immunoassay technique MeSH E05.478.567.380 – immunosorbent techniques MeSH E05.478.567.380.360 – enzyme-linked immunosorbent assay MeSH E05.478.567.380.810 – radioallergosorbent test MeSH E05.478.567.380.825 – radioimmunoprecipitation assay MeSH E05.478.567.380.830 – radioimmunosorbent test MeSH E05.478.567.639 – radioimmunoassay MeSH E05.478.567.639.405 – immunoradiometric assay MeSH E05.478.567.639.810 – radioallergosorbent test MeSH E05.478.567.639.825 – radioimmunoprecipitation assay MeSH E05.478.567.639.830 – radioimmunosorbent test
pain, redness, or swelling at the injection site; vancomycin flushing syndrome (VFS), previously known as red man syndrome (or "redman syndrome"); thrombophlebitis, which is common when administered through peripheral catheters but not when central venous catheters are used, although central venous catheters are a predisposing factor for upper-extremity deep-vein thrombosis. Damage to the kidneys (nephrotoxicity) and to the hearing (ototoxicity) were side effects of the early, impure versions of vancomycin, and were prominent in clinical trials conducted in the mid-1950s. Later trials using purer forms of vancomycin found nephrotoxicity is an infrequent adverse effect (0.1% to 1% of patients), but this is accentuated in the presence of aminoglycosides. Rare adverse effects associated with intravenous vancomycin (<0.1% of patients) include anaphylaxis, toxic epidermal necrolysis, erythema multiforme, superinfection, thrombocytopenia, neutropenia, leukopenia, tinnitus, dizziness and/or ototoxicity, and DRESS syndrome. Vancomycin can induce platelet-reactive antibodies in the patient, leading to severe thrombocytopenia and bleeding with florid petechial hemorrhages, ecchymoses, and wet purpura. Historically, vancomycin has been considered a nephrotoxic and ototoxic drug, based on numerous case reports in the medical literature following initial approval by the FDA in 1958. But as its use increased with the spread of MRSA beginning in the 1970s, toxicity risks were reassessed.
The loss of species from ecological communities, defaunation, is primarily driven by human activity. This has resulted in empty forests, ecological communities depleted of large vertebrates. In the Quaternary extinction event, the mass die-off of megafaunal variety coincided with the appearance of humans, suggesting a human influence. One hypothesis is that humans hunted large mammals, such as the woolly mammoth, into extinction. The 2019 Global Assessment Report on Biodiversity and Ecosystem Services by IPBES states that the total biomass of wild mammals has declined by 82 percent since the beginning of human civilization. Wild animals make up just 4% of mammalian biomass on earth, while humans and their domesticated animals make up 96%. Various species are predicted to become extinct in the near future, among them the rhinoceros, giraffes, and species of primates and pangolins. According to the WWF's 2020 Living Planet Report, vertebrate wildlife populations have declined by 68% since 1970 as a result of human activities, particularly overconsumption, population growth and intensive farming, which is evidence that humans have triggered a sixth mass extinction event. Hunting alone threatens hundreds of mammalian species around the world. Scientists claim that the growing demand for meat is contributing to biodiversity loss as this is a significant driver of deforestation and habitat destruction; species-rich habitats, such as significant portions of the Amazon rainforest, are being converted to agricultural land for meat production.
=== Lawsuits === In the late 1980s, Barker accused the American Humane Society and the United Activists for Animal Rights of condoning animal cruelty on the set of Project X and in several other media projects on the basis of allowing a cattle prod and a gun on set, and a rumored beating of a chimpanzee on set. American Humane responded by suing Barker for $10 million, citing libel, slander and invasion of privacy. American Humane claimed that there had been a two-year "vendetta" against them behind the accusations. In a series of public advertisements along with the lawsuit, American Humane responded to Barker's claims that his allegations were made based on insufficient and misleading information. The suit was eventually settled by Barker's insurance company, which paid American Humane $300,000. In 1994, former model Dian Parkinson filed a lawsuit against Barker alleging sexual harassment following a three-year affair while working on The Price Is Right. Parkinson, who alleged that she was extorted by threats of firing, later dropped her lawsuit, claiming the stress from the ordeal was damaging her health. In 1995, model Holly Hallstrom left The Price Is Right and later filed suit against Barker, alleging that the reason she was fired was not so much because of her 14-pound (6.4 kg) medication-mediated weight gain (as documented) but because, to Barker's displeasure, she refused to give false information to the media regarding Parkinson's suit, as she alleges Barker had requested she do.
Potassium (19K) has 25 known isotopes from 34K to 57K as well as 31K, as well as an unconfirmed report of 59K. Three of those isotopes occur naturally: the two stable forms 39K (93.26%) and 41K (6.72%), and the long-lived radioisotope 40K (0.012%). Naturally occurring radioactive 40K decays with a half-life of 1.248×109 years. 89% of those decays are to stable 40Ca by beta decay, whilst 11% are to 40Ar by either electron capture or positron emission. This latter decay branch has produced an isotopic abundance of argon on Earth which differs greatly from that seen in gas giants and stellar spectra. 40K has the longest known half-life for any positron-emitting nuclide. The long half-life of this primordial radioisotope is caused by a highly spin-forbidden transition: 40K has a nuclear spin of 4, while both of its decay daughters are even–even isotopes with spins of 0. 40K occurs in natural potassium in sufficient quantity that large bags of potassium chloride commercial salt substitutes can be used as a radioactive source for classroom demonstrations. 40K is the largest source of natural radioactivity in healthy animals and humans, greater even than 14C. In a human body of 70 kg mass, about 4,300 nuclei of 40K decay per second. The decay of 40K to 40Ar is used in potassium-argon dating of rocks. Minerals are dated by measurement of the concentration of potassium and the amount of radiogenic 40Ar that has accumulated. 40K has also been extensively used as a radioactive tracer in studies of weathering.
Sources: en.wikipedia.org
Deep learning uses several layers of neurons between the network's inputs and outputs. The multiple layers can progressively extract higher-level features from the raw input. For example, in image processing, lower layers may identify edges, while higher layers may identify the concepts relevant to a human such as digits, letters, or faces. Deep learning has been used to improve the performance of programs in subfields of artificial intelligence including computer vision, speech recognition, natural language processing, image classification and others. Deep neural networks and backpropagation had been in development since 1950. Starting in 2012, the speed of deep learning was increased one hundred-fold by switching to GPUs, and there were enormous amounts of data available on the internet (called at the time "big data") as well as curated datasets used for benchmark testing, such as ImageNet. Usage of deep learning increased in 2012–2015 due to these improvements. In 2025, Geoffrey Hinton said that, until the 2010s, "We couldn't do anything very impressive because we didn’t have enough data and we didn't have enough computation."
(2026) study the morphology of hominin limb bones from the Salawusu site (China), finding no evidence of diagnostic features of the Neanderthal lineage, and reporting morphological evidence consistent with affinities with modern humans. Li et al. (2026) report evidence from the study of the palynological record from the East China Sea continental shelf spanning the past 71,000 years indicative of presence of a cool, dry temperate grassland biome during the lowstand intervals (including the Last Glacial Maximum), as well as evidence of presence of an open-forest landscape during the milder conditions of the Marine Isotope Stage 3, and interpret their findings as supporting the interpretation of the exposed East China Sea continental shelf as a habitat facilitating the initial dispersal of early modern humans into East Asia. Zhang et al. (2026) study the features of stone tools from the Nwya Devu site (China), reporting evidence of differences from stone tool assemblages from northern Initial Upper Paleolithic sites, and interpret tools from the Nwya Devu site as either representing a regional variant of Initial Upper Paleolithic technology or resulting from a separate dispersal of blade technologies into East Asia. Totsuka et al. (2026) reconstruct the chronology of early Upper Paleolithic sites in Japan, and report evidence of rapid increase in the number of sites between 36,000 and 34,000 years ago that was likely linked to growth of the human population size. Oktaviana et al.
Drilling is carried out after studies of structural geology (at the reservoir scale), sedimentary basin analysis, and reservoir characterisation (mainly in terms of the porosity and permeability of geologic reservoir structures). Wells are drilled into oil reservoirs to extract the crude oil. "Natural lift" production methods that rely on the natural reservoir pressure to force the oil to the surface are usually sufficient for a while after reservoirs are first tapped. In some reservoirs, such as in the Middle East, the natural pressure is sufficient over a long time. The natural pressure in most reservoirs, however, eventually dissipates. Then the oil must be extracted using "artificial lift" means. Over time, these "primary" methods become less effective and "secondary" production methods may be used. A common secondary method is "waterflood" or injection of water into the reservoir to increase pressure and force the oil to the drilled shaft or "wellbore". Eventually "tertiary" or "enhanced" oil recovery methods may be used to increase the oil's flow characteristics by injecting steam, carbon dioxide and other gases or chemicals into the reservoir. In the United States, primary production methods account for less than 40 percent of the oil produced on a daily basis, secondary methods account for about 50 percent, and tertiary recovery the remaining 10 percent.
=== Resolution === The interferogram belongs in the length dimension. Fourier transform (FT) inverts the dimension, so the FT of the interferogram belongs in the reciprocal length dimension([L−1]), that is the dimension of wavenumber. The spectral resolution in cm−1 is equal to the reciprocal of the maximal OPD in cm. Thus a 4 cm−1 resolution will be obtained if the maximal OPD is 0.25 cm; this is typical of the cheaper FTIR instruments. Much higher resolution can be obtained by increasing the maximal OPD. This is not easy, as the moving mirror must travel in a near-perfect straight line. The use of corner-cube mirrors in place of the flat mirrors is helpful, as an outgoing ray from a corner-cube mirror is parallel to the incoming ray, regardless of the orientation of the mirror about axes perpendicular to the axis of the light beam. A spectrometer with 0.001 cm−1 resolution is now available commercially. The throughput advantage is important for high-resolution FTIR, as the monochromator in a dispersive instrument with the same resolution would have very narrow entrance and exit slits. In 1966 Janine Connes measured the temperature of the atmosphere of Venus by recording the vibration-rotation spectrum of Venusian CO2 at 0.1 cm−1 resolution. Michelson himself attempted to resolve the hydrogen Hα emission band in the spectrum of a hydrogen atom into its two components by using his interferometer. p25
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.